Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNA 3103 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Carina Biotech

    • Most Recent Events

    • 18 Dec 2023 According to a Carina Biotech media release, Professor Michael Brown is the principal investigator for this trial.
    • 18 Dec 2023 According to a Carina Biotech media release, first patient has been dosed in this trial. ). Enrolment in the Phase 1 segment commenced in Australia with three sites currently activated.
    • 19 Oct 2023 Planned initiation date changed from 1 Jul 2023 to 19 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top